Factors that may influence the choice for initiating apremilast or methotrexate treatment for psoriasis in real‐world clinical setting

Autor:	T. Le Guyadec, M. Kemula, G. Gabison, C. Poiraud, J-L Perrot, I. Kupfer-Bessaguet, A. Vermersch-Langlin, M. Bastien, M. Steff, P. Bilan, P. Pfister, M. Zeitoun, Céline Girard, D. Lons-Danic, T. Boyé, D. Thomas-Beaulieu, N. Quiles-Tsimaratos, A-C Fougerousse, Valérie Pallure, Edouard Begon, L. Wagner, J-B Monfort, E. Mahé, Gem Resopso, J. Parier, B. Halioua, L. Mery-Bossard, P-A Becherel, Hervé Maillard, E. Lorier, A Beauchet, N. Sultan, C. Boulard, François Maccari, M. Perrussel
Rok vydání:	2019
Předmět:	Adult Male medicine.medical_specialty Cross-sectional study Clinical Decision-Making MEDLINE Dermatology Clinical decision making Psoriasis medicine Humans Aged Methotrexate treatment business.industry Middle Aged medicine.disease Thalidomide Cross-Sectional Studies Methotrexate Infectious Diseases Multicenter study Female Dermatologic Agents Apremilast business medicine.drug
Zdroj:	Journal of the European Academy of Dermatology and Venereology. 33
ISSN:	1468-3083 0926-9959
DOI:	10.1111/jdv.15804
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::071c4e86931c54c629fc7380a4fda2b3 https://doi.org/10.1111/jdv.15804 Zobrazit plný text záznamu Plný text